Correlation Between Mereo BioPharma and Viracta Therapeutics

Can any of the company-specific risk be diversified away by investing in both Mereo BioPharma and Viracta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mereo BioPharma and Viracta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mereo BioPharma Group and Viracta Therapeutics, you can compare the effects of market volatilities on Mereo BioPharma and Viracta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mereo BioPharma with a short position of Viracta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mereo BioPharma and Viracta Therapeutics.

Diversification Opportunities for Mereo BioPharma and Viracta Therapeutics

0.76

Correlation Coefficient

Mereo BioPharma  Viracta Therapeutics

Poor diversification

The 3 months correlation between Mereo and Viracta is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and Viracta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viracta Therapeutics and Mereo BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mereo BioPharma Group are associated (or correlated) with Viracta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viracta Therapeutics has no effect on the direction of Mereo BioPharma i.e., Mereo BioPharma and Viracta Therapeutics go up and down completely randomly.

Pair Corralation between Mereo BioPharma and Viracta Therapeutics

Given the investment horizon of 90 days Mereo BioPharma Group is expected to generate 0.82 times more return on investment than Viracta Therapeutics. However, Mereo BioPharma Group is 1.22 times less risky than Viracta Therapeutics. It trades about -0.16 of its potential returns per unit of risk. Viracta Therapeutics is currently generating about -0.32 per unit of risk. If you would invest  421.00  in Mereo BioPharma Group on August 30, 2024 and sell it today you would lose (65.00) from holding Mereo BioPharma Group or give up 15.44% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Mereo BioPharma Group  vs.  Viracta Therapeutics

Mereo BioPharma Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Mereo BioPharma and Viracta Therapeutics

The main advantage of trading using opposite Mereo BioPharma and Viracta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mereo BioPharma position performs unexpectedly, Viracta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viracta Therapeutics will offset losses from the drop in Viracta Therapeutics' long position.

The idea behind Mereo BioPharma Group and Viracta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.